Pharma BD Deal Intelligence
Lantheus Holdings, Inc. / Life Molecular Imaging Ltd.
2024 · Asset Purchase · Complete
Lantheus acquired global rights from Life Molecular Imaging to the RM2 radiotheranostic pair targeting gastrin-releasing peptide receptor (GRPR), comprising the 177Lu-DOTA-RM2 radiotherapeutic and the 68Ga-DOTA-RM2 radiodiagnostic. Lantheus paid USD 35 million upfront plus undisclosed regulatory milestones and royalties, and stated it intends to initiate a Phase 1/2a study of 177Lu-DOTA-RM2 in prostate cancer in 2025 as an option for patients for whom PSMA-targeted therapy may be unsuitable.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jun 27, 2024
- Deal type Asset Purchase
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2024 deals · Lantheus Holdings, Inc. deals